Figure 5

Figure 5

Patient derived RMS cells derived from an in mouse established xenograft also form vascularized tumours in the zebrafish xenograft setting, which are responsive to MRTKI inhibition. (A), Bar graphs showing tumour area, neo-vessel length, neo-vessel frequency and SIV length for vehicle only injected as well as all FN, all FP and the FP IC-pPDX-104 injected xenografts. (B), Bar graphs showing the effect of 0.1 µM regorafenib treatment on tumour area, neo-vessel length, neo-vessel frequency and SIV length for all FN, all FP and FP IC-pPDX-104 injected xenografts. (C), Bar graphs showing the effect of 0.1 µM infigratinib treatment on tumour area, neo-vessel length, neo-vessel frequency and SIV length for all FN, all FP and FP IC-pPDX-104 injected xenografts. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001, Ordinary one-way ANOVA with Tukey’s multiple comparison’s test, Data are presented as mean values +/- SEM. n = number of xenografts (except for “% with neo-vessels”, which is number of experiments).